Lupin gets EIR from USFDA for its Ankleshwar manufacturing facility

3 Oct 2022 , 09:16 AM

Global pharma major Lupin Limited informed that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Ankleshwar manufacturing facility, located in Gujarat, India. The inspection of the facility was conducted from August 16-19, 2022.

Nilesh Gupta, Managing Director, Lupin commented, “We are very happy to have received the EIR for our Ankleshwar facility from USFDA. We remain committed to enhancing compliance and quality standards across all our manufacturing sites.”

On Monday early morning trade, Lupin Ltd is currently trading at Rs685.50 per share up by Rs5.9 or 0.87% from its previous closing of Rs679.60 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]